gemcitabine / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

58 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemcitabine / Generic mfg.
PanCAN-SR1, NCT04581343: A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients

Checkmark Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Nov 2022 - Nov 2022: Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Active, not recruiting
1b
10
US
Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine, Ilaris, Abraxane
Pancreatic Cancer Action Network, Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
03/23
08/23
NCT05557851: Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Recruiting
1b
36
RoW
Minnelide
Minneamrita Therapeutics LLC
Metastatic Adenocarcinoma of the Pancreas
06/24
12/24
NCT03554044: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Active, not recruiting
1b
20
US
Anastrozole, Arimidex, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, ICI 182,780, ZD9238, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC, OncoVEXGM-CSF, Tamoxifen, Nolvadex, Nab paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin
University of California, San Francisco, Amgen
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
04/25
04/25
OMO-103-02, NCT06059001: Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

Recruiting
1b
18
Europe
OMO-103, Nab-Paclitaxel, Gemcitabine
Peptomyc S.L.
Metastatic Pancreatic Cancer
12/25
03/26
NCT02009449: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Checkmark In combination with pembrolizumab/ nivolumab for advanced RCC
Sep 2019 - Sep 2019: In combination with pembrolizumab/ nivolumab for advanced RCC
Checkmark Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Sep 2017 - Sep 2017: Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Checkmark From AM0010/AM0010 + anti-PD-1 in NSCLC at ESMO 2017 [screenshot]
More
Active, not recruiting
1
350
US
Pegilodecakin, LY3500518, AM0010, PEGylated recombinant human Interleukin-10, PEG-rHuIL-10, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, Taxol or taxotere and paraplatin or platinol, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), Eloxatin®/Leucovorin/5-FU, gemcitabine/nab-paclitaxel, Gemzar/Abraxane ABI-007, Capecitabine, Xeloda, Pazopanib, GW786034, Pembrolizumab, Keytruda, MK-3475, Paclitaxel, nivolumab, Keytruda, Gemcitabine/carboplatin, gemzar/paraplatin
Eli Lilly and Company, ARMO BioSciences
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
02/19
08/24
NCT02495896: Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Terminated
1
61
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, nab-paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, protein-bound paclitaxel, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
University of Southern California, National Cancer Institute (NCI), Vasgene Therapeutics, Inc
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
05/19
05/19
2017-003935-12: A phase 1 trial to assess the safety, tolerability and anti-tumor activity of increasing doses of the drugs AZD6738 and gemcitabine in combination.

Not yet recruiting
1
55
Europe
Gemcitabine, AZD6738, L01BC05, Powder for solution for infusion, Film-coated tablet, Concentrate for solution for infusion, Gemcitabine
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, AstraZeneca
Locally advanced or metastatic solid tumour., Solid tumour cancer (any type of cancer apart from leukaemia or lymphoma) which has spread., Diseases [C] - Cancer [C04]
 
 
NCT03421353: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Hourglass Jan 2019 - Dec 2020 : Data from P1b/2 trial of Imfinzi in combination with AZD9150 for NSCLC
Active, not recruiting
1
76
US
AZD9150, Durvalumab, MEDI4736, Cisplatin, 5-Flourouracil, 5-FU, Carboplatin, Gemcitabine, Nab-paclitaxel
AstraZeneca
Advanced Solid Tumours
01/20
06/24
NCT03252808: Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.

Active, not recruiting
1
36
Japan
TBI-1401(HF10), HF10, canerpaturev, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, TS-1, Tegafur-gimeracil-oteracil potassium
Takara Bio Inc.
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
02/20
03/35
NCT02937272: A Study of LY3200882 in Participants With Solid Tumors

Active, not recruiting
1
223
Europe, Canada, Japan, US, RoW
LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy
Eli Lilly and Company
Solid Tumor
02/20
08/25
NCT04046887: Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

Terminated
1
14
US
Lonsurf, Gemcitabine, Nab-Paclitaxel
Patrick Joseph Loehrer Sr., Indiana University, Taiho Oncology, Inc.
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
05/21
10/23
NCT04282070: SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
1
91
RoW
SHR-1701, SHR-1701 Injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin Injection, Albumin Paclitaxel, nab-Paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
04/22
12/22
NCT04156828: Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Terminated
1
12
US
Copanlisib, 1032568-63-0, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Gemcitabine, dFdCyd, Difluorodeoxycytidine, 1-(2-Oxo-4-amino-1, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Nealorin, Novoplatinum, Paraplatin, Paraplatine, Platinwas, Ribocarbo, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin Depot, Auricularum, Auxiloson, Baycadron, Baycuten, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone, Deltafluorene, Desameton, Dexa-Mamallet, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Rituximab, 174722-31-7, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, rituximab-abbs, RTXM83, Truxima, Pegfilgrastim, 208265-92-3, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Nyvepria, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Udenyca, Ziextenzo
University of Washington, Bayer
Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
04/22
06/23
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
NCT03884556: TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Hourglass Jan 2022 - Dec 2022 : Early proof of concept data from P1/1b trial for solid tumors
Completed
1
56
US
TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
Trishula Therapeutics, Inc.
Solid Tumor, Lymphoma
11/22
09/23
NCT04306900: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Completed
1
185
US, RoW
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Trishula Therapeutics, Inc., AbbVie
Solid Tumor, Adult
11/22
03/24
NCT04247126: A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Completed
1
105
US
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Syros Pharmaceuticals
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
01/23
03/23
SGNS40-001, NCT02376699: Safety Study of SEA-CD40 in Cancer Patients

Checkmark Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Jan 2022 - Jan 2022: Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Terminated
1
159
US
Intravenous (IV) SEA-CD40, SEA-CD40, Pembrolizumab, Keytruda, Subcutaneous (SC) SEA-CD40, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane
Seagen Inc., Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
03/23
04/23
St. Jude ELIOT, NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Active, not recruiting
1
21
US
Prexasertib, LY2606368, Cyclophosphamide, Cytoxan, Gemcitabine, 2'-deoxy-2',2' difluorocytidine monohydrochloride, LY18801, Gemzar®, filgrastim, G-CSF, peg-filgrastim, pegylated filgrastim, PEG filgrastim, Neulasta®
St. Jude Children's Research Hospital, Eli Lilly and Company
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
05/23
10/24
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Calendar Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
NCT05299164: GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Active, not recruiting
1
18
RoW
Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level 2, Liposomal Mitoxantrone Hydrochloride dose level 3, Liposomal Mitoxantrone Hydrochloride dose level 4
Institute of Hematology & Blood Diseases Hospital, China, CSPC Ouyi Pharmaceutical Co., Ltd.
Non Hodgkin Lymphoma
12/23
12/25
MASCT-I, NCT03034304: A Phase I Clinical Study for Evaluating the Safety and Efficacy of in Patients With Advanced Solid Tumors

Recruiting
1
193
RoW
MASCT-I, Ifosfamide, PD1 antibody, Adriamycin, Gemcitabine, Cisplatin, Carboplatin
SYZ Cell Therapy Co..
Advanced Solid Tumors
07/23
07/23
INDUCE-1, NCT02723955: Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors

Completed
1
829
Europe, Canada, Japan, US, RoW
feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms
07/23
07/23
NCT04634539: Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Active, not recruiting
1
18
US
Gemcitabine, Nab-paclitaxel, L-glutamine, Endari
Jun Gong, MD, Emmaus Medical, Inc.
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
07/23
07/25
NCT04802980: A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

Recruiting
1
72
RoW
HB002.1T, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin
Huabo Biopharm Co., Ltd.
Solid Tumor
07/23
09/23
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
1
200
Europe, Japan, US, RoW
LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab
Eli Lilly and Company, Loxo Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
07/23
05/25
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Not yet recruiting
1
24
NA
JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
Onconic Therapeutics Inc.
Pancreatic Ductal Adenocarcinoma
08/23
08/23
KEYNOTE-A62, NCT04336098: Study of SRF617 in Patients With Advanced Solid Tumors

Completed
1
85
Canada, US
SRF617, Gemcitabine, Gemzar®, Albumin-Bound Paclitaxel, Abraxane®, Pembrolizumab, Keytruda®
Coherus Biosciences, Inc., Surface Oncology, Merck Sharp & Dohme LLC
Advanced Solid Tumor
08/23
08/23
NCT06182072: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
28
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, nab paclitaxel, (G-nP)
ProDa BioTech, LLC, University of Alabama at Birmingham, Georgia State University
Pancreatic Ductal Carcinoma
07/25
10/25
UCT01097-001, NCT04761601: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Terminated
1
32
US
UCT-01-097, Gemcitabine, Gemzar, Paclitaxel, Abraxane
1200 Pharma, LLC
Advanced Solid Tumor
02/24
02/24
ATRiUM, NCT03669601: AZD6738 & Gemcitabine as Combination Therapy

Recruiting
1
55
Europe
AZD6738, Gemcitabine, Gemzar
CCTU- Cancer Theme, AstraZeneca
Cancer
09/23
09/24
NCT05193604: A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Terminated
1
29
RoW
TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection, Paclitaxel for injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Pancreatic Carcinoma
11/23
11/23
MAGNETIC, NCT05147272: Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Active, not recruiting
1
104
Europe, Canada, US
RP-6306 (oral PKMYT1 inhibitor), Gemcitabine (IV)
Repare Therapeutics
Adult Solid Tumor
12/24
04/25
NCT03507491: Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Active, not recruiting
1
24
US
Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane
Emory University, Celgene Corporation
Cancer
06/24
06/24
NCT06164327: Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
75
RoW
BEBT-908 for Injection, CUDC-908, Rituximab Injection, IDEC-C2B8, Gemcitabine Hydrochloride for Injection, NSC 613327, Oxaliplatin Injection, NSC 266046, Etoposide Injection, VP-16213, Ifosfamide for Injection, NSC109724, Carboplatin Injection, NSC 241240
BeBetter Med Inc
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
10/25
11/25
CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
1
18
Canada
Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab
Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation
Lymphoma, B-Cell
12/25
07/26
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
ZN-c3-002, NCT04516447: A Study of ZN-c3 in Patients With Ovarian Cancer

Jul 2023 - Dec 2023: Data from trial in combination with chemotherapy for platinum-resistant ovarian cancer
Recruiting
1
140
Europe, US, RoW
ZN-c3, Study drug, Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Bevacizumab
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
12/24
02/27
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Recruiting
1
264
US
MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
BioNTech Research & Development, Inc.
Pancreatic Cancer
08/24
10/26
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Recruiting
1
64
US
GP-2250, gemcitabine
Geistlich Pharma AG, Translational Drug Development
Pancreatic Cancer, Adult
09/24
12/24
NCT06360354: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Recruiting
1
282
US
AMG 193, Gemcitabine, Nab-paclitaxel, Cisplatin, Pembrolizumab, Modified FOLFIRINOX
Amgen
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
11/25
11/27
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
NCT06447662: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Not yet recruiting
1
330
US
PF-07934040, PF-4040, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, Cetuximab, Erbitux, Fluorouracil, 5-FU, 5-fluorouracil, Oxaliplatin, Eloxatin, Leucovorin, Folinic Acid, Wellcovorin, calcium folinate, Leucovorin Calcium, Bevacizumab, Zirabev, Avastin, Pembrolizumab, Pembro, Lambrolizumab, MK-3475, Keytruda, pemetrexed, Alimta, Cisplatin, Platinol, Cisplatinum, neoplatin, Paclitaxel, Taxol, Onxol, Carboplatin, Paraplatin, Stricarb
Pfizer
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
07/27
07/28
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Recruiting
1
187
Europe, US
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Toray Industries, Inc
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/25
03/25
NCT00479128: Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Active, not recruiting
1
80
US
Bortezomib, Velcade, LDP-341, MLN341, PS-341, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Doxorubicin, Adriamycin, AD, Hydroxydaunomycin hydrochloride
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Solid Tumor, Urethral Cancer
09/24
09/24
NCT04338763: RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

Recruiting
1
48
RoW
RP72, Rise Prot-72, Gemcitabine
Rise Biopharmaceuticals, Inc., T-TOP Clinical Research Co., Ltd.
Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
10/24
12/25
REVOLUTION, NCT04787991: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting
1
45
US
Nivolumab (Cohort A), Opdivo, Ipilimumab (Cohort A, B and C), Yervoy, Hydroxychloroquine (HCQ) (Cohort B), Plaquenil, Nab-paclitaxel (nP) (Cohort A, B and C), Abraxane, Gemcitabine (gem) (Cohort A, B and C), Gemzar, NG350A (Cohort C)
Cancer Insight, LLC, Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Metastatic Pancreatic Adenocarcinoma
10/24
01/25
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting
1
60
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
02/25
02/26
MK-0482-001, NCT03918278: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Active, not recruiting
1
230
Europe, Canada, US, RoW
MK-0482, pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin ®, Pemetrexed, Alimta
Merck Sharp & Dohme LLC
Neoplasms
02/25
02/25
NCT06076837: The Seven Trial: Exploiting the Unfolded Protein Response

Not yet recruiting
1
12
US
Botensilimab, AGEN1811, Balstilimab, AGEN2034, Chloroquine Phosphate, Aralen, Celecoxib, Celebrex
HonorHealth Research Institute, Translational Genomics Research Institute, University of Arizona, Agenus Inc.
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
06/25
12/25
NCT05867121: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
120
Europe, Japan, US, RoW
RO7496353, SOF 10, Atezolizumab, RO554126 7; Tecentriq, Capecitabine, S-1, Tegafur/Gimeracil/Oteracil potassium, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Genentech, Inc., Chugai Pharmaceutical Co.
Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
12/25
12/25
ADCT-601-102, NCT05389462: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Recruiting
1
260
Europe, US
ADCT-601, Mipasetamab uzoptirine, Gemcitabine
ADC Therapeutics S.A.
Advanced Solid Tumors
08/26
08/27
NCT05325281: CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Recruiting
1
24
US
CPI-613® (Dose level -1.0 250 mg/m^2), Devimistat, alpha-lipoic acid analogue CPI-613, CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2), CPI-613® (Dose level 3.0 1,500 mg/m^2), CPI-613® Maximum Tolerated Dose (MTD), Gemcitabine, Gemzar®, Intensity-modulated Radiation Therapy
Medical College of Wisconsin, Cornerstone Pharmaceuticals, Barbara Ann Karmanos Cancer Institute
Pancreas Adenocarcinoma
08/26
08/27
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Recruiting
1
430
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
NCT05006794: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Recruiting
1
195
US, RoW
GS-9716, Docetaxel, sacituzumab govitecan-hziy
Gilead Sciences
Solid Malignancies
01/27
01/27
NCT03233139: Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Checkmark From trial for advanced malignancies in Japanese patients at ASCO-SITC 2019 [screenshot]
Mar 2019 - Mar 2019: From trial for advanced malignancies in Japanese patients at ASCO-SITC 2019 [screenshot]
Recruiting
1
145
Japan
Cemiplimab, REGN2810, Libtayo, Ipilimumab, Platinum-doublet chemotherapy, Gemcitabine, Gemzar, Pemetrexed, Alimta, Paclitaxel, Taxol, Fianlimab
Regeneron Pharmaceuticals
Advanced Malignancies
12/27
03/30
NCT05919537: Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Recruiting
1
68
RoW
HMBD-001, Docetaxel, Nab-paclitaxel, Gemcitabine
Hummingbird Bioscience
Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
03/31
03/31

Download Options